Abstract
Diabetes has become the fifth leading cause of death across developed markets, and cases of the disease are forecast to grow by 7.1% across the globe by 2013. The market for innovative diabetes treatments will be driven by this projected rise in prevalence, together with the substantial unmet need for drugs that can effectively halt or reverse disease progression. Although extended lifecycle management for existing antidiabetic therapies may offer sales growth in the short term, the development of new drugs from novel classes will become increasingly important in the future. However, the potential introduction of stricter regulations for diabetes drug development and recent setbacks for novel products have increased speculation about the potential of innovative treatments. ' Innovations in the Management of Diabetes: Next generation treatments and market dynamics' is a new report published by Business Insights that analyzes the emerging drug classes, novel drug delivery technologies and future growth drivers of the diabetes market. This report explores the major trends and issues affecting the development of novel products and assesses the future potential of leading innovations. The major areas of unmet need in the market are identified and the currently marketed portfolios and developmental compounds of key companies operating within the sector are assessed. This report also examines recent concerns about the safety profiles of marketed products and the possible implementation of stricter FDA regulations. Explore the latest trends and innovations in diabetes treatments, assess the currently marketed portfolios and pipelines of leading players and identify future market opportunities with this report.
Table of Contents
Executive Summary
- Introduction
- Currently marketed innovatives
- Future drivers of growth and innovation
- Key companies and pipelines
- Future trends and implications
Chapter 1 Introduction
- Summary
- Introduction
- Disease description
- Type 1 diabetes
- Type 2 diabetes
- An increasing global health concern
- Increasing patient population
- Underdiagnosed and undertreated
- Economic burden
Chapter 2 Currently marketed innovatives
- Summary
- Introduction
- Current growth drivers
- Insulins
- Leading marketed innovatives within insulin
- Exubera
- Oral anti-diabetics (OADs)
- Leading marketed innovatives in OADs
- Other diabetic drugs
- Leading marketed innovatives in other diabetic drugs
Chapter 3 Future drivers of growth and innovation
- Summary
- Introduction
- Unmet need
- Key events in the global diabetes market
- ACCORD trial halted 18 months early
- Inhaled insulins fail to impact market
- FDA considers stricter rules for diabetes drugs
- Toward the prevention and further treatment of diabetes
- Non-invasive forms of insulin via new drug delivery technologies
- Inhaled insulins
- Future potential of inhaled insulins
- Oral insulins
- Future potential of oral insulins
- Insulin patches
- Future potential of insulin patches
- Emerging new drug classes: targeting underlying causes
- Incretin mimetics: GLP-1 agonists and DDP-IV inhibitors
- GLP-1 agonists in development
- Novel GLP-1 agonists addressing unmet need
- DDP-IV inhibitors in development
- Novel DDP-IV inhibitors addressing unmet need
- PPAR agonists
- PPAR agonists in development
- Novel PPAR agonists addressing unmet need
- Sodium glucose co-transporter (SGLT) inhibitors
- SGLT inhibitors in development
- Cannabinoid-1 (CB1) receptor antagonists
- CB-1 receptor antagonists in development
- Glucokinase activators (GKA)
- Glucokinase activators in development
- Other novel drugs in development
- Protein tyrosine phosphatase 1B (PT1B) inhibitors
- Glycogen synthase kinase-3 (GSK-3) inhibitors
- 11-beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitors
- GPR119 agonists
- Cell transplantation and innovative therapies
Chapter 4 Key companies and pipelines
- Summary
- Introduction
- Leading competitive strategies
- Lifecycle management
- Diversification
- Franchise development
- New market entry
- Leading players
- Novo Nordisk
- Currently marketed innovatives profile
- R&D/innovatives profile
- Takeda
- Currently marketed innovatives profile
- R&D/innovatives profile
- Sanofi-Aventis
- Currently marketed innovatives profile
- R&D/innovatives profile
- GSK
- Currently marketed innovatives profile
- R&D/innovatives profile
- Lilly
- Currently marketed innovatives profile
- R&D/innovatives profile
- Merck.
- Currently marketed innovatives profile
- R&D/innovatives profile
Chapter 5 Future trends and implications
- Summary
- Introduction
- Future market growth
- Competitive strategy and future potential
Chapter 6 Appendix
- IMS data
- Index
List of Figures
- Figure 3.1: Unmet needs in diabetes, 2008
- Figure 3.2: Innovative diabetes pipeline, 2007
- Figure 3.3: Addressing unmet need of novel GLP-1 agonists versus insulin
- Figure 3.4: Addressing unmet need of novel DDP-IV inhibitors versus TZDs
- Figure 3.5: Addressing unmet need of novel PPAR agonists* versus TZDs
- Figure 4.6: Competitive dynamics of the leading players in the diabetes market, 2007
- Figure 5.7: Drivers and resistors of growth in the innovative diabetes market, 2007
- Figure 5.8: Forecast sales growth for the global diabetes market, 2007-12
- Figure 5.9: Outlook for leading pharmaceutical companies in the innovative diabetes market
List of Tables
- Table 2.1: Breakdown of the global diabetes market by drug class, 2003-07
- Table 4.2: Leading diabetes companies*, 2006-07
- Table 4.3: Novo Nordisk' s currently marketed innovative diabetes profile, 2003-07
- Table 4.4: Novo Nordisk' s diabetes R&D/innovatives profile
- Table 4.5: Takeda' s currently marketed innovative diabetes profile, 2003-07
- Table 4.6: Takeda' s diabetes R&D/innovatives profile
- Table 4.7: Sanofi-Aventis' currently marketed innovative diabetes profile, 2003-07
- Table 4.8: Sanofi-Aventis' diabetes R&D/innovatives profile
- Table 4.9: GSK' s currently marketed innovative diabetes profile, 2003-07
- Table 4.10: GSK' s diabetes R&D/innovatives profile
- Table 4.11: Lilly' s currently marketed diabetes innovative diabetes, 2003-07
- Table 4.12: Lilly' s diabetes R&D/innovatives profile
- Table 4.13: Merck' s currently marketed innovative diabetes profile, 2003-07
- Table 4.14: Merck' s diabetes R&D/innovatives profile
